Introduction: Next-generation sequencing (NGS) is commonly used in clinical practice to decide treatment based on genomic information. This study was performed to optimize the proportion of actionable gene profiling and treatment based on genetic alterations in breast cancer at one of the cancer centers in Japan. Methods: Patients with breast cancer who reported NGS results at one of the cancer centers in Japan from August 2019 to December 2023 were retrospectively investigated by reviewing their electronic medical records. Patients were examined using the OncoGuide NCC Oncopanel System, FoundationOne® CDx, or FoundationOne® Liquid CDx. The evidence levels for drug recommendation were added for each gene alteration according to the guidelines from three Japanese oncology-related societies. “Actionable alterations” were those at evidence levels A–D, including high microsatellite instability and high tumor mutation burden status. “Patients with recommended drug” (approved, investigational, and off-label drugs) were defined as those who were selected by the Molecular Tumor Board. Results: Of the 106 patients, 54 were tested using the NCC Oncopanel System and 50 using FoundationOne CDx. The most frequent alterations were TP53 mutations (52.8%) and PIK3CA mutations (31.1%). Of the 56 patients (52.8%) with recommended drugs, 11 (10.4%) received genome-matched therapy and only three (2.8%) participated in clinical trials. The most common reason for not receiving genome-matched therapy was patient refusal for personal reasons, although clinical trials were available (18 patients). Conclusion: The top reasons for patients not receiving the recommended genome-matched therapy were factors related to the patient, including a number of prior treatments higher than what was allowed by the eligibility criteria of the clinical trials, and poor physical condition. Most patients received four or more regimens of cytotoxic chemotherapy before NGS. NGS is only available at the late phase of treatment in Japan, which would constitute a problem for the treatment of breast cancer.

1.
World Health Organization [Internet]
. Newsroom. [cited 2024 October 17]. Available from: https://www.who.int/news-room/fact-sheets/detail/breast-cancer
2.
Cancer Statistics [Internet]
.
Cancer information service, national cancer center, Japan (vital statistics of Japan
.
Ministry of Health, Labour and Welfare
. [cited 2024 October 17]. Available from: https://ganjoho.jp/reg_stat/statistics/stat/summary.html
3.
Fumagalli
C
,
Ranghiero
A
,
Gandini
S
,
Corso
F
,
Taormina
S
,
De Camilli
E
, et al
.
Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses
.
Breast Cancer Res
.
2020
;
22
(
1
):
107
.
4.
Ando
Y
,
Shimoi
T
,
Suzuki
T
,
Ueno
H
,
Okita
N
,
Nakamura
K
.
Genomic medicine in clinical practice: national genomic medicine program in Japan
.
Cancer Biol Med
.
2023
;
21
(
1
):
4
9
.
5.
André
F
,
Ciruelos
E
,
Rubovszky
G
,
Campone
M
,
Loibl
S
,
Rugo
HS
, et al
.
Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer
.
N Engl J Med
.
2019
;
380
(
20
):
1929
40
.
6.
Rugo
HS
,
Lerebours
F
,
Ciruelos
E
,
Drullinsky
P
,
Ruiz-Borrego
M
,
Neven
P
, et al
.
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
.
Lancet Oncol
.
2021
;
22
(
4
):
489
98
. Erratum in: Lancet Oncol. 2021;22(5):e184.
7.
Bidard
FC
,
Kaklamani
VG
,
Neven
P
,
Streich
G
,
Montero
AJ
,
Forget
F
, et al
.
Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial
.
J Clin Oncol
.
2022
;
40
(
28
):
3246
56
. Erratum in: J Clin Oncol. 2023;41(23):3962.
8.
Turner
NC
,
Oliveira
M
,
Howell
SJ
,
Dalenc
F
,
Cortes
J
,
Gomez Moreno
HL
, et al
.
Capivasertib in hormone receptor-positive advanced breast cancer
.
N Engl J Med
.
2023
;
388
(
22
):
2058
70
.
9.
Kawaji
H
,
Kubo
M
,
Yamashita
N
,
Yamamoto
H
,
Kai
M
,
Kajihara
A
, et al
.
Comprehensive molecular profiling broadens treatment options for breast cancer patients
.
Cancer Med
.
2021
;
10
(
2
):
529
39
.
11.
Foundation Medicine Inc.. [Internet] [cited 2024 October 17]. Available from: https://www.foundationmedicine.com/
12.
Allison
KH
,
Hammond
MEH
,
Dowsett
M
,
McKernin
SE
,
Carey
LA
,
Fitzgibbons
PL
, et al
.
Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update
.
J Clin Oncol
.
2020
;
38
(
12
):
1346
66
.
13.
Wolff
AC
,
Somerfield
MR
,
Dowsett
M
,
Hammond
MEH
,
Hayes
DF
,
McShane
LM
, et al
.
Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-college of American pathologists guideline update
.
J Clin Oncol
.
2023
;
41
(
22
):
3867
72
.
14.
Myriad genetics [internet] [cited 2024 October 17]. Available from: https://myriadgenetics.jp/all-products/bracanalysis/ovary-cancer/
15.
Japanese Cancer Association [Internet]
. Clinical practice guidance base on gene panel testing using Next generation sequencers, etc. Revision 2.1 [cited 2024 October 17]. Available from: https://www.cancer.or.jp/archive/topics/20171013_guidance_2.pdf
16.
CIViC—clinical interpretation of variants in cancer [internet]
[cited 2024 October 17]. Available from: https://civicdb.org/welcome
17.
OncoKB™—MSK’s precision oncology knowledge base [internet] [cited 2024 October 17]. Available from: https://www.oncokb.org/
18.
Liang
X
,
Vacher
S
,
Boulai
A
,
Bernard
V
,
Baulande
S
,
Bohec
M
, et al
.
Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer
.
Breast Cancer Res
.
2018
;
20
(
1
):
88
.
19.
Kanda
Y
.
Investigation of the freely available easy-to-use software “EZR” for medical statistics
.
Bone Marrow Transplant
.
2013
;
48
(
3
):
452
8
.
20.
R Core Team
.
R: a language and environment for statistical computing
.
Vienna, Austria
:
R Foundation for Statistical Computing
;
2021
. [internet] [cited 2024 October 17]. Available from: https://www.R-project.org/
21.
Löhr
JM
.
The FIRST-dx study takes steps toward personalized cancer therapy
.
JAMA Netw Open
.
2023
;
6
(
7
):
e2323298
.
22.
Mizuno
T
,
Yoshida
T
,
Sunami
K
,
Koyama
T
,
Okita
N
,
Kubo
T
, et al
.
Study protocol for NCCH1908 (UPFRONT-trial): a prospective clinical trial to evaluate the feasibility and utility of comprehensive genomic profiling prior to the initial systemic treatment in advanced solid tumour patients
.
Jpn J Clin Oncol
.
2021
;
51
(
12
):
1757
60
.
23.
Sunami
K
,
Ichikawa
H
,
Kubo
T
,
Kato
M
,
Fujiwara
Y
,
Shimomura
A
, et al
.
Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: a hospital-based study
.
Cancer Sci
.
2019
;
110
(
4
):
1480
90
.
24.
van Geelen
CT
,
Savas
P
,
Teo
ZL
,
Luen
SJ
,
Weng
CF
,
Ko
YA
, et al
.
Clinical implications of prospective genomic profiling of metastatic breast cancer patients
.
Breast Cancer Res
.
2020
;
22
(
1
):
91
.
25.
Brett
JO
,
Spring
LM
,
Bardia
A
,
Wander
SA
.
ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer
.
Breast Cancer Res
.
2021
;
23
(
1
):
85
.
26.
Alva
AS
,
Mangat
PK
,
Garrett-Mayer
E
,
Halabi
S
,
Hansra
D
,
Calfa
CJ
, et al
.
Pembrolizumab in patients with metastatic breast cancer with high tumor mutational burden: results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study
.
J Clin Oncol
.
2021
;
39
(
22
):
2443
51
.
27.
Cardoso
F
,
McArthur
HL
,
Schmid
P
,
Cortés
J
,
Harbeck
N
,
Telli
ML
, et al
.
LBA21 KEYNOTE-756: phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + Endocrine Therapy (ET) for early-stage high-risk ER+/HER2– breast cancer
.
Ann Oncol
.
2023
;
34
(
2
):
S1260
1
.
28.
Loi
S
,
Curigliano
G
,
Salgado
RF
,
Romero Diaz
RI
,
Delaloge
S
,
Rojas
C
, et al
.
LBA20 A randomized, double-blind trial of nivolumab (NIVO) vs placebo (PBO) with neoadjuvant chemotherapy (NACT) followed by adjuvant endocrine therapy (ET) ± NIVO in patients (pts) with high-risk, ER+ HER2− primary breast cancer (BC)
.
Ann Oncol
.
2023
;
34
(
2
):
S1259
60
.
You do not currently have access to this content.